Lexagene Announces 2017 Annual General and Special Meeting Voting Results

VANCOUVER, British Columbia, Sept. 14, 2017 (GLOBE NEWSWIRE) — LexaGene Holdings Inc. (OTCQB:LXXGF) (TSX-V:LXG) (the “Company”), per TSX Venture reporting requirements, is pleased to announce the voting results for election of its Board of Directors at the Annual General and Special Meeting of Shareholders held on September 12, 2017 in Vancouver, British Columbia.  The director nominees as listed in the Information Circular dated August 1, 2017 were elected as directors of the Company at the meeting to serve until the next annual general meeting.

Name of Directors
Dr. Jack Regan
Daryl Rebeck
Tom Slezak
Dr. Eric Olsen
Dr. Manohar Furtado

Each of the other matters put forward before shareholders for consideration and approval at the Meeting, as described in the Circular, was duly approved.

Also, the Company announces that it has granted to Dr. Furtado, a new director, and newly hired consultants of the Company stock options (the “Options”) to purchase up to 270,000 common shares at a price of $1.05 per common share vesting 10% on the grant date and 15% every six months thereafter expiring on March 12, 2021. In addition, the Company granted 315,000 restricted share units (“RSU”) to these individuals. The RSU trigger date is March 12, 2018 and expiry date September 12, 2020. The Options and RSU have been granted in accordance with the terms of the Company’s current omnibus plan.


Dr. Jack Regan: Founder, Chief Executive Officer and Director

For further information, please contact:

Dr. Jack Regan, Chief Executive Officer, jackregan@lexagene.com

The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors — including the availability of funds, the results of financing efforts, the success of technology development efforts, the cost to procure critical parts, performance of the instrument, market acceptance of the technology, regulatory acceptance, and licensing issues — that could cause actual results to differ materially from the Company’s expectations as disclosed in the Company’s documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For Marketing inquiries, please email: